Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Rod who wrote (7450)	3/7/1999 9:55:00 PM
From: papa bear	Read Replies (1) \| Respond to of 8116

CYTO is certainly looking attractive technically right now. Looks like there was a triple bottom (goingback to about Fall last year), as well as improving MACD and stochastics. CYTO is acting like it did just before the Annual Report came out last March (when it hit 2-1/2). Maybe it's about time again... Any thoughts, especially from charters...

To: Rod who wrote (7450)	3/10/1999 10:15:00 AM
From: Chuca Marsh	Respond to of 8116

Luck has nothing to do with it: ( Management) ( Good Management-now! )RE: Berlex and CYTOGEN Announce Launch of New Marketing Campaign For QUADRAMET(R) Cancer Pain Drug PR Newswire - March 10, 1999 09:58 Focus on Prescribing Cancer Physicians and Product Awareness PRINCETON and MONTVILLE, N.J., March 10 /PRNewswire/ -- CYTOGEN Corporation (Nasdaq: CYTO) and Berlex Laboratories, Inc. announced the launch of Berlex's national marketing campaign for CYTOGEN's QUADRAMET(R) (Samarium 153 Lexidronam Injection) drug to treat bone pain caused by metastatic cancer. The comprehensive Berlex sales, education and advertising program is designed to build broad market presence with cancer physicians in the U.S. Berlex is CYTOGEN's exclusive marketing partner for QUADRAMET(R). Berlex developed the integrated marketing and medical campaign to build comprehensive awareness of QUADRAMET(R)'s unique features in cancer bone pain management. The sales campaign targets medical oncologists, radiation oncologists, and nuclear medicine physicians -- key doctors whose patients might be candidates for QUADRAMET(R). The new Berlex campaign will deploy a team of 130 dedicated oncology sales and hospital-based representatives, a combination of two strategic Berlex sales forces with an established and experienced presence in the oncology and hospital-based markets. In addition, Berlex's existing scientific liaison team will provide technical and clinical expertise to support sales team efforts. The campaign includes professional education initiatives for each target physician discipline. Berlex will hold a series of interactive conference and speaker programs throughout the country featuring oncology, nuclear and radiation physicians experienced with QUADRAMET(R). Berlex also will introduce national advertising in major oncology, nuclear medicine, and urological journals as well as a direct mail effort. Committed to developing novel therapeutics that address unmet medical needs, Berlex Laboratories, Inc. researches, manufactures, and markets ethical pharmaceuticals in three strategic areas: Diagnostic Imaging, Female Healthcare, and Therapeutics for life-threatening and disabling diseases. In the Therapeutics category, Berlex also markets FLUDARA(R) (fludarabine phosphate) to treat refractory chronic lymphocetic leukemia, BETASERON(R) (Interferon beta-1b) to treat relapsing-remitting multiple sclerosis, and BETAPACE(R) (sotolol HCI) to treat life-threatening ventricular arrhythmias. Berlex business divisions are located in Montville and Wayne, New Jersey, and in Richmond, California. For more information, visit the Berlex website at www.berlex.com. CYTOGEN is a biopharmaceutical company engaged in the development, manufacture, and commercialization of products for the targeted delivery of diagnostic and therapeutic substances directly to disease sites. CYTOGEN has demonstrated its ability to develop new technology from early discovery through clinical development, regulatory approval, and commercial scale biologic manufacturing. In addition to QUADRAMET(R), CYTOGEN has two other FDA-approved products on the market: PROSTASCINT(R) (kit for the preparation of Indium In111 Capromab Pendetide), a prostate cancer imaging agent, and ONCOSCINT(R) (CR/OV imaging agent), an imaging agent for colorectal and ovarian cancers. Visit CYTOGEN's website at www.cytogen.com for more information and full prescribing information on CYTOGEN's products. QUADRAMET(R) causes bone marrow suppression. Prior to administration, clinical benefits should be judged to outweigh the risk in patients having compromised bone marrow reserves or undergoing therapy that causes myelosuppression. Information in this press release, which is not historical, is forward looking and involves risks and uncertainties. Actual results may differ materially for various reasons, including CYTOGEN's ability to carry out its business plan and successful development and commercial acceptance of CYTOGEN's products, and other factors discussed in CYTOGEN's filings with the Securities and Exchange Commission. SOURCE CYTOGEN Corporation /CONTACT: CYTOGEN Corporate Communications, 609-750-8224, or Wendy K. Neininger of Berlex Laboratories, 973-276-2043/ /Web site: berlex.com /Web site: cytogen.com Chuca P.S.- I lost my ass of CYTOW, CYTO, and don't forget the CALLS and found what I needed: freeyellow.com P.P.S.- Catchup folks, check out JNNE thread and my favorite DD: maxamgold.com